ArticleInternational journal of biological sciences2016
A Group of Novel Serum Diagnostic Biomarkers for Multidrug-Resistant Tuberculosis by iTRAQ-2D LC-MS/MS and Solexa Sequencing.
Article in International journal of biological sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Type 2 diabetes mellitus associated microRNAs in tuberculosis susceptibility: a systematic review and bioinformatic analysis.Frontiers in endocrinology · 2026Pooled it
- Different MicroRNAs expression inRNA biology · 2026Review
- Clinical differentiation between pediatric pulmonary tuberculosis andExperimental and therapeutic medicine · 2026Review
- Integrated metabolomic and transcriptomic analysis reveals novel plasma biomarkers and metabolic pathway dysregulation in latent tuberculosis infection.Microbiology spectrum · 2026Article
- Advances in functional transcriptome analysis of Mycobacterium tuberculosis: a review.Molecular genetics and genomics : MGG · 2026Review
- Exploration of plasma exosomal miR-122-5p and its related targets KNG1 and C3 in the diagnosis of drug-resistant tuberculosis.Scientific reports · 2025Article
- Plasma proteomics for biomarker discovery in childhood tuberculosis.Nature communications · 2025Article
- Circulating MicroRNAs as Biomarkers for the Early Diagnosis of Lung Cancer and Its Differentiation from Tuberculosis.Diagnostics (Basel, Switzerland) · 2024Article
- Exploring miRNAs' Based Modeling Approach for Predicting PIRA in Multiple Sclerosis: A Comprehensive Analysis.International journal of molecular sciences · 2024Article
- Single molecule measurements of microRNAs in the serum of patients with pulmonary tuberculosis.Frontiers in immunology · 2024Article
- Downregulation of monocyte miRNAs: implications for immune dysfunction and disease severity in drug-resistant tuberculosis.Frontiers in immunology · 2023Article
- MiR-25 blunts autophagy and promotes the survival ofiScience · 2022Article
- Non-Coding RNAs in Tuberculosis Epidemiology: Platforms and Approaches for Investigating the Genome's Dark Matter.International journal of molecular sciences · 2022Review
- Article
- Micro RNAs as potential biomarkers in tuberculosis: A systematic review.Non-coding RNA research · 2022Article
- Study on the Predictive Value of P53 Protein Expression in Brain Metastasis in NSCLC and the Mechanism of miR-424 Reversing Platinum Resistance in NSCLC.Contrast media & molecular imaging · 2022Article
- MicroRNAs as immune regulators and biomarkers in tuberculosis.Frontiers in immunology · 2022Review
- Article
- Association between active pulmonary tuberculosis and circulating microRNAs: a preliminary study from TurkeyTurkish journal of medical sciences · 2021Article
- A Dual Marker for Monitoring MDR-TB Treatment: Host-Derived miRNAs andFrontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidemic of pulmonary tuberculosis (TB), especially multidrug-resistance tuberculosis (MDR-TB) presented a major challenge for TB treatment today. We performed iTRAQ labeling coupled with two-dimensional liquid chromatography-tandem mass spectrometry (2D LC-MS/MS) and Solexa sequencing among MDR-TB patients, drug-sensitive tuberculosis (DS-TB) patients, and healthy controls. A total of 50 differentially expressed proteins and 43 differentially expressed miRNAs (fold change >1.50 or <0.60, P<0.05) were identified in the MDR-TB patients compared to both DS-TB patients and healthy controls. We found that 22.00% of differentially expressed proteins and 32.56% of differentially expressed miRNAs were related, and could construct a network mainly in complement and coagulation cascades. Significant differences in CD44 antigen (CD44), coagulation factor XI (F11), kininogen-1 (KNG1), miR-4433b-5p, miR-424-5p, and miR-199b-5p were found among MDR-TB patients, DS-TB patients and healthy controls (P<0.05) by enzyme-linked immunosorbent assay (ELISA) and SYBR green qRT-PCR validation. A strong negative correlation, consistent with the target gene prediction, was found between miR-199b-5p and KNG1 (r=-0.232, P=0.017). Moreover, we established the MDR-TB diagnostic model based on five biomarkers (CD44, KNG1, miR-4433b-5p, miR-424-5p, and miR-199b-5p). Our study proposes potential biomarkers for MDR-TB diagnosis, and also provides a new experimental basis to understand the pathogenesis of MDR-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.